GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
812
c/glp1science·posted 2 months ago by u/elin_lundgren

incretin: what the trials say vs what this community says

Speculation The Quiet One ×2

incretin: what the trials say vs what this community says. Making the case below, and I expect to lose some of it in the comments.

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

1,027 up / 215 down83% upvoted40 commentsid xy16zf12 May 2026

40 comments

28 in this archive, depth 4

best — the order this archive was captured in

u/gastric_emptying_gMOD130 points·2 months ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
u/tomas_broberg107 points·2 months ago

Do you have the paper, or a summary of it?

replysharereportpermalink
u/elin_lundgrenOP-14 points·2 months ago

Which receptor arm are you attributing that to?

replysharereportpermalink
u/laila_almeida40 points·2 months ago

mechanism explains a direction, not a magnitude

replysharereportpermalink
u/asks_dumb_questions40 points·2 months ago

Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.

replysharereportpermalink
u/bilal_osei44 points·2 months ago

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

replysharereportpermalink
u/sig_figs_sammod · analytical90 points·2 months ago

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

replysharereportpermalink
u/georgi_chowdhury41 points·2 months ago

Receptor expression in a tissue is necessary but not sufficient for an effect.

Agreed — and it is why the central and peripheral stories are complementary rather than rival.

replysharereportpermalink
u/titration_marshalmod · c/semaglutide47 points·2 months ago

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

replysharereportpermalink
u/enzo_petrescu29 points·2 months ago

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

replysharereportpermalink
u/rasmus_kimani13 points·2 months ago

incretin effect first, then everything else in this board makes sense

replysharereportpermalink
u/zeynep_villalobos8 points·2 months ago

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

replysharereportpermalink
u/sanne_delgado33 points·2 months ago

receptor agonism is not the same as receptor activation in every tissue

replysharereportpermalink
u/ingrid_correia42 points·2 months ago·edited

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

replysharereportpermalink
u/hedda_adeyemi19 points·2 months ago·edited

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are

ingrid_correia is right that mechanism gives direction and not magnitude. Worth pinning.

replysharereportpermalink
load more comments (1) →
u/elodie_grimaldi32 points·2 months ago

What does the discussion section say about the limitation you are glossing?

replysharereportpermalink
u/neha_krastev19 points·2 months ago

gastric emptying slows, it does not stop

replysharereportpermalink
[removed]13 points·2 months ago

[removed by moderator]

replysharereportpermalink
u/gradient_goblin20 points·2 months ago

Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.

replysharereportpermalink
u/emil_agyeman6 points·2 months ago

glucagon agonism sounds paradoxical until you read the energy expenditure work

replysharereportpermalink
u/elin_lundgrenOP2 points·2 months ago

Is that from a human study or a preclinical model?

replysharereportpermalink
load more comments (2) →
u/santiago_rasmussen10 points·2 months ago·edited

That conflates receptor affinity with clinical potency. They are related and they are not the same thing.

replysharereportpermalink
u/gustav_vermeulen6 points·2 months ago·edited

That conflates receptor affinity with clinical potency.

This is the concept everything else on this board is downstream of.

replysharereportpermalink
u/yusuf_ramos7 points·2 months ago

read the discussion section, that is where the honesty lives

replysharereportpermalink
u/bilal_osei2 points·2 months ago

Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.